A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy
Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Huang, Qin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Chemical Research in Chinese Universities - Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012, 38(2022), 4 vom: 25. Mai, Seite 928-934 |
|---|---|
| Übergeordnetes Werk: |
volume:38 ; year:2022 ; number:4 ; day:25 ; month:05 ; pages:928-934 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40242-022-2116-8 |
|---|
| Katalog-ID: |
SPR050850067 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR050850067 | ||
| 003 | DE-627 | ||
| 005 | 20230509103641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230507s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40242-022-2116-8 |2 doi | |
| 035 | |a (DE-627)SPR050850067 | ||
| 035 | |a (SPR)s40242-022-2116-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Qin |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 | ||
| 520 | |a Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. | ||
| 650 | 4 | |a Targeted therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug combination cancer therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aptamer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a DNA nanostructure |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Liu, Xin |4 aut | |
| 700 | 1 | |a Zhang, Pengge |4 aut | |
| 700 | 1 | |a Wu, Zhan |4 aut | |
| 700 | 1 | |a Zhao, Zilong |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical Research in Chinese Universities |d Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 |g 38(2022), 4 vom: 25. Mai, Seite 928-934 |w (DE-627)SPR03290777X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:4 |g day:25 |g month:05 |g pages:928-934 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40242-022-2116-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 4 |b 25 |c 05 |h 928-934 | ||
| author_variant |
q h qh x l xl p z pz z w zw z z zz |
|---|---|
| matchkey_str |
huangqinliuxinzhangpenggewuzhanzhaozilon:2022----:daaoricrynardfndrgobnt |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1007/s40242-022-2116-8 doi (DE-627)SPR050850067 (SPR)s40242-022-2116-8-e DE-627 ger DE-627 rakwb eng Huang, Qin verfasserin aut A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 Liu, Xin aut Zhang, Pengge aut Wu, Zhan aut Zhao, Zilong aut Enthalten in Chemical Research in Chinese Universities Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 38(2022), 4 vom: 25. Mai, Seite 928-934 (DE-627)SPR03290777X nnns volume:38 year:2022 number:4 day:25 month:05 pages:928-934 https://dx.doi.org/10.1007/s40242-022-2116-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 38 2022 4 25 05 928-934 |
| spelling |
10.1007/s40242-022-2116-8 doi (DE-627)SPR050850067 (SPR)s40242-022-2116-8-e DE-627 ger DE-627 rakwb eng Huang, Qin verfasserin aut A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 Liu, Xin aut Zhang, Pengge aut Wu, Zhan aut Zhao, Zilong aut Enthalten in Chemical Research in Chinese Universities Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 38(2022), 4 vom: 25. Mai, Seite 928-934 (DE-627)SPR03290777X nnns volume:38 year:2022 number:4 day:25 month:05 pages:928-934 https://dx.doi.org/10.1007/s40242-022-2116-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 38 2022 4 25 05 928-934 |
| allfields_unstemmed |
10.1007/s40242-022-2116-8 doi (DE-627)SPR050850067 (SPR)s40242-022-2116-8-e DE-627 ger DE-627 rakwb eng Huang, Qin verfasserin aut A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 Liu, Xin aut Zhang, Pengge aut Wu, Zhan aut Zhao, Zilong aut Enthalten in Chemical Research in Chinese Universities Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 38(2022), 4 vom: 25. Mai, Seite 928-934 (DE-627)SPR03290777X nnns volume:38 year:2022 number:4 day:25 month:05 pages:928-934 https://dx.doi.org/10.1007/s40242-022-2116-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 38 2022 4 25 05 928-934 |
| allfieldsGer |
10.1007/s40242-022-2116-8 doi (DE-627)SPR050850067 (SPR)s40242-022-2116-8-e DE-627 ger DE-627 rakwb eng Huang, Qin verfasserin aut A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 Liu, Xin aut Zhang, Pengge aut Wu, Zhan aut Zhao, Zilong aut Enthalten in Chemical Research in Chinese Universities Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 38(2022), 4 vom: 25. Mai, Seite 928-934 (DE-627)SPR03290777X nnns volume:38 year:2022 number:4 day:25 month:05 pages:928-934 https://dx.doi.org/10.1007/s40242-022-2116-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 38 2022 4 25 05 928-934 |
| allfieldsSound |
10.1007/s40242-022-2116-8 doi (DE-627)SPR050850067 (SPR)s40242-022-2116-8-e DE-627 ger DE-627 rakwb eng Huang, Qin verfasserin aut A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 Liu, Xin aut Zhang, Pengge aut Wu, Zhan aut Zhao, Zilong aut Enthalten in Chemical Research in Chinese Universities Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012 38(2022), 4 vom: 25. Mai, Seite 928-934 (DE-627)SPR03290777X nnns volume:38 year:2022 number:4 day:25 month:05 pages:928-934 https://dx.doi.org/10.1007/s40242-022-2116-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 38 2022 4 25 05 928-934 |
| language |
English |
| source |
Enthalten in Chemical Research in Chinese Universities 38(2022), 4 vom: 25. Mai, Seite 928-934 volume:38 year:2022 number:4 day:25 month:05 pages:928-934 |
| sourceStr |
Enthalten in Chemical Research in Chinese Universities 38(2022), 4 vom: 25. Mai, Seite 928-934 volume:38 year:2022 number:4 day:25 month:05 pages:928-934 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Targeted therapy Drug combination cancer therapy Aptamer DNA nanostructure |
| isfreeaccess_bool |
false |
| container_title |
Chemical Research in Chinese Universities |
| authorswithroles_txt_mv |
Huang, Qin @@aut@@ Liu, Xin @@aut@@ Zhang, Pengge @@aut@@ Wu, Zhan @@aut@@ Zhao, Zilong @@aut@@ |
| publishDateDaySort_date |
2022-05-25T00:00:00Z |
| hierarchy_top_id |
SPR03290777X |
| id |
SPR050850067 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR050850067</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509103641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230507s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40242-022-2116-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR050850067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40242-022-2116-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Huang, Qin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug combination cancer therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aptamer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DNA nanostructure</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Xin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Pengge</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Zhan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Zilong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Chemical Research in Chinese Universities</subfield><subfield code="d">Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012</subfield><subfield code="g">38(2022), 4 vom: 25. Mai, Seite 928-934</subfield><subfield code="w">(DE-627)SPR03290777X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:25</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:928-934</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40242-022-2116-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">25</subfield><subfield code="c">05</subfield><subfield code="h">928-934</subfield></datafield></record></collection>
|
| author |
Huang, Qin |
| spellingShingle |
Huang, Qin misc Targeted therapy misc Drug combination cancer therapy misc Aptamer misc DNA nanostructure A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| authorStr |
Huang, Qin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR03290777X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy Targeted therapy (dpeaa)DE-He213 Drug combination cancer therapy (dpeaa)DE-He213 Aptamer (dpeaa)DE-He213 DNA nanostructure (dpeaa)DE-He213 |
| topic |
misc Targeted therapy misc Drug combination cancer therapy misc Aptamer misc DNA nanostructure |
| topic_unstemmed |
misc Targeted therapy misc Drug combination cancer therapy misc Aptamer misc DNA nanostructure |
| topic_browse |
misc Targeted therapy misc Drug combination cancer therapy misc Aptamer misc DNA nanostructure |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Chemical Research in Chinese Universities |
| hierarchy_parent_id |
SPR03290777X |
| hierarchy_top_title |
Chemical Research in Chinese Universities |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR03290777X |
| title |
A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| ctrlnum |
(DE-627)SPR050850067 (SPR)s40242-022-2116-8-e |
| title_full |
A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| author_sort |
Huang, Qin |
| journal |
Chemical Research in Chinese Universities |
| journalStr |
Chemical Research in Chinese Universities |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
928 |
| author_browse |
Huang, Qin Liu, Xin Zhang, Pengge Wu, Zhan Zhao, Zilong |
| container_volume |
38 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Huang, Qin |
| doi_str_mv |
10.1007/s40242-022-2116-8 |
| title_sort |
dna nano-train carrying a predefined drug combination for cancer therapy |
| title_auth |
A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| abstract |
Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 |
| abstractGer |
Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 |
| abstract_unstemmed |
Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy. © Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
4 |
| title_short |
A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy |
| url |
https://dx.doi.org/10.1007/s40242-022-2116-8 |
| remote_bool |
true |
| author2 |
Liu, Xin Zhang, Pengge Wu, Zhan Zhao, Zilong |
| author2Str |
Liu, Xin Zhang, Pengge Wu, Zhan Zhao, Zilong |
| ppnlink |
SPR03290777X |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40242-022-2116-8 |
| up_date |
2024-07-03T18:10:42.313Z |
| _version_ |
1803582431366742016 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR050850067</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230509103641.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230507s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40242-022-2116-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR050850067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40242-022-2116-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Huang, Qin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="2"><subfield code="a">A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Jilin University, The Editorial Department of Chemical Research in Chinese Universities and Springer-Verlag GmbH 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Targeted therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug combination cancer therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aptamer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">DNA nanostructure</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Xin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Pengge</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Zhan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Zilong</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Chemical Research in Chinese Universities</subfield><subfield code="d">Jilin University and The Editorial Department of Chemical Research in Chinese Universities, 2012</subfield><subfield code="g">38(2022), 4 vom: 25. Mai, Seite 928-934</subfield><subfield code="w">(DE-627)SPR03290777X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:4</subfield><subfield code="g">day:25</subfield><subfield code="g">month:05</subfield><subfield code="g">pages:928-934</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40242-022-2116-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2022</subfield><subfield code="e">4</subfield><subfield code="b">25</subfield><subfield code="c">05</subfield><subfield code="h">928-934</subfield></datafield></record></collection>
|
| score |
7.4007015 |